On May 19, 2026 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, reported that Dr. Bing Hou has been appointed Chief Scientific Officer, reporting directly to Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Hou’s appointment underscores Antengene’s commitment to strengthening its innovation-driven R&D model as a global biotech company. In this role, Dr. Hou will lead Antengene’s efforts across Drug Discovery, Translational Medicine, and Chemistry, Manufacturing and Controls (CMC), with a focus on deepening the Company’s research engine and building a pipeline of next-generation therapeutic candidates with transformational potential.

Since joining Antengene in 2019, Dr. Hou has been a key member of the Company’s scientific leadership team, and prior to this appointment, served as Vice President, Head of Discovery Science & Translational Medicine. During his tenure, he has built and led a high-caliber discovery organization, helped guide Antengene’s R&D initiatives, advanced internally discovered programs into clinical development, and played an important role in establishing newly developed proprietary platforms designed to support future innovation programs.

"We are very pleased to appoint Dr. Bing Hou as Chief Scientific Officer of Antengene," said Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene. "Dr. Hou has made significant contributions to shaping Antengene’s scientific strategy and strengthening our internal research capabilities. Under his leadership, Antengene has built and advanced AnTenGager, the Company’s proprietary T-cell engager (TCE) 2.0 platform with broad applicability across autoimmune diseases, solid tumors and hematological malignancies, as well as other novel programs and platform technologies that support our next-generation pipeline. The global license agreement Antengene entered into with UCB for ATG-201, a CD19 x CD3 TCE developed from the AnTenGager platform for B cell-related autoimmune diseases, further highlights the strategic value of Antengene’s proprietary discovery capabilities. As we enter our next stage of growth, we look forward to Dr. Hou’s continued leadership in expanding our innovative pipeline, and bringing forward transformative therapies for patients globally."

"I am honored and excited to step into the role of Chief Scientific Officer at Antengene," said Dr. Bing Hou, Chief Scientific Officer of Antengene. "Antengene is advancing a number of highly promising programs across oncology and autoimmune diseases, and I believe we are well positioned to build a next-generation pipeline grounded in rigorous biology, differentiated mechanisms and platform innovation. Looking ahead, we will continue to focus on programs with the potential to address significant unmet medical needs, including T cell engagers developed from our proprietary AnTenGager platform; ATG-125, a B7-H3 x PD-L1 bispecific antibody-drug conjugate (ADC) designed to combine ADC and immuno-oncology mechanisms; and ATG-207, a globally first-in-class αCD3-TGF-β bifunctional fusion protein for T cell-driven autoimmune diseases. I look forward to continuing to work closely with the Antengene team to translate our differentiated science and platform capabilities into a robust pipeline of innovative medicines."

Dr. Hou received his Ph.D. in Biomedicine from the University of Leeds in the United Kingdom. He has published multiple high-impact research papers as first author or corresponding author in leading journals including Nature, Science Advances, and Cancer Research. He has filed more than 40 patent applications for novel therapeutics. As an inventor and/or principal leader, he has advanced multiple first-in-class or best-in-class drug candidates into various stages of clinical development.

(Press release, Antengene, MAY 19, 2026, View Source [SID1234665878])

On May 19, 2026 Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, reported that the first patient has been dosed in its Phase 1/2 STAR-GBM study. The trial is designed to assess safety, tolerability, pharmacokinetics, and preliminary signals of clinical activity with longitudinal imaging in adults with newly diagnosed glioblastoma (GBM). With support from the National Cancer Institute (NCI/NIH), the trial is being conducted in collaboration with the Mayo Clinic across its Minnesota, Florida, and Arizona campuses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MT-125 is a first-in-class inhibitor of non-muscle myosin II (NMII), designed to disrupt the physical mechanics of tumor cells to induce tumor cell collapse and death through non-redundant mechanisms distinct from any existing therapy.

"This marks the transition of MT-125 from a strong mechanistic and preclinical foundation into clinical testing in patients with one of the most aggressive cancers," said Courtney Miller, PhD, Chief Executive Officer of Myosin Therapeutics. "Our research shows that targeting the mechanical dependencies of tumor cells represents a fundamentally different approach to cancer treatment, and this study is designed to test that hypothesis directly in patients with glioblastoma."

"MT-125 introduces a novel therapeutic strategy that is distinct from conventional cytotoxic and targeted approaches," said Karen Smith, MD, PhD, MBA, LLM, Chief Medical Officer of Myosin Therapeutics. "Partnering with Mayo Clinic allows us to efficiently evaluate both safety and early biological activity in a patient population with significant unmet need."

MT-125 has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma, supporting an accelerated regulatory pathway. In addition to GBM, MT-125 is being developed for other treatment-resistant cancers, including acute myeloid leukemia and pancreatic cancer. Additional information on the STAR GBM study is available at clinicaltrials.gov (NCT07185880).

The STAR-GBM trial is supported by the National Cancer Institute and by a syndicate of life sciences investors and philanthropic organizations.

(Press release, Myosin Therapeutics, MAY 19, 2026, View Source [SID1234665877])

On May 19, 2026 Matter Bio reported the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Lm-LLO-TT, the company’s lead therapeutic candidate, for a first-in-human Phase 1/2a clinical trial in patients with pancreatic ductal adenocarcinoma (PDAC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

If the IND is cleared by the FDA, the Phase 1/2a study is expected to evaluate the safety, tolerability, dose optimization, and preliminary anti-tumor activity of Lm-LLO-TT in patients with PDAC, one of the deadliest and most treatment-resistant solid tumors.

"Submitting our first IND for Lm-LLO-TT is a landmark achievement for Matter Bio and the beginning of our transition into a clinical-stage company," said Chris Bradley, Chief Executive Officer of Matter Bio. "We believe this program represents a differentiated and potentially transformative approach for pancreatic cancer, a disease where patients urgently need better options. Our team has worked with urgency and discipline to bring this therapy to the clinic, and we are excited to take this next step."

Lm-LLO-TT is Matter Bio’s attenuated Listeria monocytogenes-based immunotherapy candidate, designed to stimulate tumor-directed memory immune responses in difficult-to-treat cancers. The company is advancing the program in PDAC, where current treatment options remain limited and patient outcomes remain poor.

"Lm-LLO-TT was created to mobilize the immune system in a way that could meaningfully change how we treat difficult solid tumors such as pancreatic cancer," said Claudia Gravekamp, PhD, inventor of Lm-LLO-TT. "The promise of this platform lies in its potential to both engage memory immune mechanisms and target a tumor environment that has remained resistant to many existing approaches. Seeing this program reach IND submission is deeply meaningful and brings us closer to evaluating its potential in patients."

The IND submission represents a major milestone for Matter Bio as the company moves from preclinical development toward clinical evaluation of its lead oncology program. Matter Bio expects to provide additional updates following completion of the FDA’s review of the IND.

(Press release, Matter Bio, MAY 19, 2026, View Source [SID1234665876])

On May 19, 2026 MEKanistic Therapeutics, a biotechnology company developing first-in-class precision medicines designed to overcome cancer resistance mechanisms, reported that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for MTX-531, the company’s lead oncology candidate.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With the IND now in effect, MEKanistic may proceed with its planned Phase 1 clinical study of MTX-531, subject to standard study start-up activities.

MTX-531 is a potential first-in-class small molecule designed to selectively inhibit PI3K and EGFR, two signaling pathways implicated in tumor growth, survival and adaptive resistance.

"IND clearance marks an important milestone for MEKanistic and advances MTX-531 into the clinic," said Danny Cunagin, chief executive officer of MEKanistic Therapeutics. "We believe MTX-531’s differentiated dual-targeting approach has the potential to address meaningful unmet needs in oncology, provide new options for cancer patients and support a new treatment approach for hard-to-treat cancers."

The Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of MTX-531 in patients with advanced solid tumors characterized by dysregulated EGFR and/or PI3K signaling, including head and neck and endometrial cancers and other tumor types in which these pathways are implicated. The study will include dose-escalation with expansion cohorts at multiple U.S. sites, with first-patient dosing anticipated in the third quarter of 2026.

Preclinical findings published in Nature Cancer in 2024 demonstrated potent inhibition of EGFR and PI3K, durable tumor regressions and a differentiated tolerability profile. IND-enabling toxicology studies were supported through the National Cancer Institute’s Experimental Therapeutics, or NExT, Program.

About MTX-531

MTX-531 is a dual inhibitor of PI3K and EGFR designed to block key signaling pathways involved in tumor progression and adaptive resistance.

(Press release, Mekanistic Therapeutics, MAY 19, 2026, View Source [SID1234665875])

On May 19, 2026 Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, reported that nine abstracts featuring the latest data on its growing portfolio and pipeline will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting, held from May 30–June 2, in Los Angeles, CA. The presentations will showcase expanding clinical and preclinical evidence supporting novel PET imaging agents designed to improve prostate cancer detection, including findings from an intra-patient, head-to-head comparator study of POSLUMA (flotufolastat F 18) and piflufolastat F 18.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Across multiple studies, POSLUMA demonstrated strong performance in detecting biochemical recurrence following radical prostatectomy, particularly at low prostate-specific antigen (PSA) levels where conventional imaging remains limited. Additional data from a prospective clinical study underscores the potential utility of Axumin (fluciclovine F 18) in patients with negative or inconclusive prostate-specific membrane antigen (PSMA) PET scans, supporting continued innovation in prostate cancer imaging.

"PET radiopharmaceuticals can transform uncertainty into precision by providing clinicians with early insights to identify clinically meaningful answers when decisions cannot wait," said Marco Campione, President and CEO of Blue Earth Diagnostics. "The data presented at SNMMI showcase our commitment to advancing nuclear medicine and enhancing patient outcomes through cutting-edge molecular imaging solutions, which facilitate precise, timely, and confident clinical decision-making."

Blue Earth Diagnostics invites attendees of the 2026 SNMMI Annual Meeting to participate in the Satellite Symposium titled, "Precision in PSMA: Why Agent Selection Matters More Than Ever" on Sunday, May 31, from 11:15 AM to 12:15 PM PT in Petree Hall C. Additionally, please visit the Bracco | Blue Earth Diagnostics Exhibit Booth #1823. For complete details on the sessions and a list of scientific presentations, please check the SNMMI online program.

POSLUMA (flotufolastat F 18)
DATE: Sunday, May 31, 2026
Title: Intra-patient Contemporaneous Comparator Study of the Qualitative Assessment of Urinary Radioactivity of 18F-Piflufolastat and 18F Flotufolastat PET/CT in Patients with Low PSA Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
Presenter: Phillip H. Kuo, MD, Kuo Radiology LLC
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 261637

DATE: Sunday, May 31, 2026
Title: Intra-patient Contemporaneous Comparator Study of Normal-Organ Distribution of PSMA-Targeting PET Radiopharmaceuticals, 18F-Piflufolastat and 18F-Flotufolastat, in Patients with Low PSA Biochemical Recurrence of Prostate Cancer after Radical Prostatectomy
Presenter: Phillip H. Kuo, MD, Kuo Radiology LLC
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 261643

DATE: Sunday, May 31, 2026
Title: Positive Predictive Value of 18F-Flotufolastat PET in Patients with Biochemical Recurrence of Prostate Cancer: Radio-Guided Salvage Surgery and Histological Validation
Presenter: Daniel Sasse, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine München, Germany
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 202066

DATE: Sunday, May 31, 2026
Title: Intraindividual Comparison of Unspecific Bone Uptake Between 18F-Flotufolastat and 18F-PSMA-1007 PET/CT in Patients with Prostate Cancer
Presenter: Daniel Sasse, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine München, Germany
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 261004

DATE: Sunday, May 31, 2026
Title: Real-world Detection Efficacy of ¹⁸F-Flotufolastat PET/CT
Presenter: Daniel Sasse, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine München, Germany
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 262312

DATE: Sunday, May 31, 2026
Title: Tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer (mHSPC): Initial Results from PSMATrack
Presenter: Heather Jacene, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Session Type: Poster presentation
Session Time: 5:30 – 6:15 PM CT
Abstract ID.: 262165

Axumin (fluciclovine F 18)
DATE: Sunday, May 31, 2026
Title: The REFINE Study – A Prospective Clinical Trial: Uncovering Prostate Cancer Biochemical Recurrence with 18F-Fluciclovine After Negative PSMA PET
Presenter: Theo Lorenzini, Technical University of Munich, School of Medicine, TUM Klinikum rechts der Isar, Department of Nuclear Medicine Munich, Germany
Session Type: Oral presentation
Session Time: 1:20 – 1:30 PM PT
Abstract ID.: 262074

DATE: Tuesday, June 2, 2026
Title: Imaging Heterogeneity in Neuroendocrine Prostate Cancer on Paired PSMA and F18-Fluciclovine PET/CT
Presenter: Heather Jacene, MD, Dana-Farber Cancer Institute, Boston, Massachusetts
Session Type: Poster presentation
Session Time: 11:30 – 12:15 pm PT
Abstract ID.: 261277

64Cu-rhPSMA-7.3/Pipeline
DATE: Tuesday, June 2, 2026
Title: 64Cu-rhPSMA-7.3 for Imaging Prostate Cancer: A Preclinical Proof of Concept Study
Presenter: George Pope
Session Type: Poster presentation
Session Time: 11:30 – 12:15 PM CT
Abstract ID.: 261612

(Press release, Blue Earth Diagnostics, MAY 19, 2026, View Source [SID1234665874])